Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 696 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatitis, Chronic Clear all

Conditions: Hepatitis Delta Virus
Interventions: Peginterferon Lambda-1a; Drug
Lead sponsor: Eiger BioPharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 7
States / cities: Los Angeles, California • Redwood City, California • San Francisco, California + 2 more

Conditions: End-stage Kidney Disease
Interventions: Inform Me: web-based education tool; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 21 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Birmingham, Alabama • Chicago, Illinois

Conditions: Hepatitis B, Hepatitis, Liver Diseases
Interventions: All approved therapies for the treatment of Chronic Hepatitis B (CHB); Other
Lead sponsor: Target PharmaSolutions, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,708 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 30
States / cities: Phoenix, Arizona • Los Angeles, California • Pasadena, California + 21 more

Conditions: Hepatocellular Carcinoma
Interventions: Nivolumab, Sorafenib, Ipilimumab, Cabozantinib; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 657 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 10
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Pensacola, Florida + 7 more

Conditions: Hepatitis C, Chronic
Interventions: Copegus, PEGASYS, RO5024048 1500mg, RO5024048 3000mg; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 17
States / cities: La Jolla, California • Long Beach, California • Sacramento, California + 13 more

Conditions: Recurrent Chronic Hepatitis C Virus, Post Liver Transplant
Interventions: Sofosbuvir, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 8
States / cities: San Francisco, California • Indianapolis, Indiana • Kansas City, Kansas + 4 more

Conditions: Hepatitis C
Interventions: Mogroside sweetener (PureLo); Dietary Supplement
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hepatitis C
Interventions: PSI-352938, PSI-7977; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chronic Hepatitis B
Interventions: Entecavir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 31
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 28 more

Conditions: Chronic Hepatitis C Virus Infection
Interventions: ABT-333, Placebo for ABT-333, Pegylated interferon, Ribavirin; Drug · Other
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 7
States / cities: Anaheim, California • Los Angeles, California • Orlando, Florida + 4 more

Conditions: Hepatitis C, HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Hepatocellular Cancer
Interventions: Sorafenib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Cryptogenic Cirrhosis, Cryptogenic Chronic Hepatitis
Interventions: skin punch biopsy collection, Blood collection, Urine sample collection; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hepatitis C, Chronic Hepatitis C
Interventions: Mailer, In-person recruitment, EHR Alert; Other
Lead sponsor: National Opinion Research Center; Other
Eligibility: 47 Years to 69 Years
Enrollment: 29,607 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Birmingham, Alabama • Detroit, Michigan • New York, New York

Conditions: Chronic Hepatitis B
Interventions: ACH126, 433; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 13
States / cities: Los Angeles, California • Orange, California • Pasadena, California + 8 more

Conditions: End Stage Liver Disease, Hepatitis C
Interventions: Daclizumub, Tacrolimus, Cyclosporine, MMF; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hepatitis C, Chronic
Interventions: peginterferon alfa-2a [Pegasys], Copegus; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 22 more

Conditions: Hepatitis C
Interventions: miravirsen, saline; Drug
Lead sponsor: Santaris Pharma A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Autoimmune Hepatitis
Interventions: LiverMultiscan; Device
Lead sponsor: Perspectum; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Chronic Hepatitis B
Interventions: VIR-2218 and peginterferon alfa-2a; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Hepatitis B Virus Infection, Hepatitis B
Interventions: Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 5
States / cities: San Francisco, California • San Jose, California • Minneapolis, Minnesota + 2 more

Conditions: Hepatitis C
Interventions: SOF/VEL/VOX, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 43
States / cities: Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more

Conditions: Hepatitis C
Interventions: Ribavirin, Mericitabine, Peginterferon Alfa-2a, Placebo, Telaprevir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 15
States / cities: Birmingham, Alabama • Long Beach, California • Sacramento, California + 12 more

Conditions: Hepatitis C
Interventions: Placebo, TG4040; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 2
States / cities: St Louis, Missouri • Cincinnati, Ohio

Search by objective public record fields.

Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV

Optimizing Kidney Transplant Informed Consent

An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.

Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant

The Effects of Mogroside Sweetener on Viral Load in TreatmenT Naive Genotype 1 (GT 1) Subjects CHC

Open-Label Hepatic Impairment Study

A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Leukapheresis for Research on HCV-Coinfected Patients

HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)

Bartonella in Liver Transplant Patients

Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C

Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B

Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection

PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.

Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects

AIH Risk Stratification With Multiparametric MRI

VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy

A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C

TG4040 in Patients With Chronic HCV